drugset / Trial / NCT05399368
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase 2 study of RPT193 in adults with atopic dermatitis
Timeline
- Start
- 2022-06-07
- Primary completion
- 2024-05-24
- Completion
- 2024-05-24
Outcome
Outcome not reported
Stopped: “Study on clinical hold by FDA”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RPT193 | Unknown | 50 mg | Oral |
| Subject | RPT193 | Unknown | 200 mg | Oral |
| Subject | RPT193 | Unknown | 400 mg | Oral |